Results 151 to 160 of about 3,521,155 (317)

Peripheral complement interactions with amyloid β peptide in Alzheimer's disease: Polymorphisms, structure, and function of complement receptor 1

, 2018
Jenny U. Johansson, William D. Brubaker, Harold S. Javitz, Andrew W. Bergen, Denise Nishita, Abhishek Trigunaite, Andrés B Crane, Justine Ceballos, Diego Mastroeni, Andrea J. Tenner, Marwan N. Sabbagh, Joseph Rogers   +11 more
openalex   +2 more sources

The Human Intrinsic Factor-Vitamin B12 Receptor,Cubilin: Molecular Characterization and Chromosomal Mapping of the Gene to 10p Within the Autosomal Recessive Megaloblastic Anemia (MGA1) Region [PDF]

, 1998
Renata Kozyraki, Mette Kristiansen, Asli Silahtaroglu, Claus Hansen, Christian Jacobsen, Niels Tommerup, P Verroust, Søren K. Moestrup   +7 more
openalex   +1 more source

Emerging role of ARHGAP29 in melanoma cell phenotype switching

Molecular Oncology, EarlyView.
This study gives first insights into the role of ARHGAP29 in malignant melanoma. ARHGAP29 was revealed to be connected to tumor cell plasticity, promoting a mesenchymal‐like, invasive phenotype and driving tumor progression. Further, it modulates cell spreading by influencing RhoA/ROCK signaling and affects SMAD2 activity. Rho GTPase‐activating protein
Beatrice Charlotte Tröster, Melanie Kappelmann‐Fenzl, Anja Katrin Bosserhoff, Nicole Rachinger   +3 more
wiley   +1 more source

SGLT-2 Inhibitors and GLP-1 Receptor Agonists as Combination Therapy in Type 2 Diabetes. [PDF]

Curr Diab Rep
Liakos A, Karagiannis T, Avgerinos I, Bekiari E.   +3 more
europepmc   +1 more source

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

Molecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Corinna Bang, Bjørn Naume, Johannes R. Hov, Jon Amund Kyte   +7 more
wiley   +1 more source

Breast cancer liver metastases and the impact of receptor expression on survival. [PDF]

Clin Exp Metastasis
Hansson E, Sundén M, Wadsten C, Rask G, Andersson A, Sund M, Hemmingsson O.   +6 more
europepmc   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Inter-individual variability of neurotransmitter receptor and transporter density in the human brain. [PDF]

Brain Struct Funct
Hansen JY, Tuisku J, Johansson J, Chang Z, McGinnity CJ, Beliveau V, Guimond S, Ganz M, Nørgaard M, Galovic M, Bezgin G, Cox SML, Hietala J, Leyton M, Kobayashi E, Rosa-Neto P, Funck T, Palomero-Gallagher N, Knudsen GM, Marsden P, Hammers A, Nummenmaa L, Tuominen L, Misic B.   +23 more
europepmc   +1 more source

Nitric Oxide, NOC-12, and S-Nitrosoglutathione Modulate the Skeletal Muscle Calcium Release Channel/Ryanodine Receptor by Different Mechanisms [PDF]

, 2003
Junhui Sun, Le Xu, Jerry P. Eu, Jonathan S. Stamler, Gerhard Meissner   +4 more
openalex   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source